A recent study reveals that individuals who come off new slimming jabs like semaglutide or tirzepatide tend to recover shed pounds far faster than those who end traditional lifestyle plans.
Published data in a major health publication shows that while obese individuals can lose a large proportion of their body weight while undergoing treatment, the mass comes back at an average rate of nearly a kilo each month upon discontinuation.
"Individuals using these medications need to be cognizant of the potential of fast weight regain when the treatment concludes," stated lead investigator Dr. Susan Jebb.
Such speed of recovery implies a return to pre-treatment mass in about a year and a half.
Analyzing Approaches
The study, which reviewed 37 of trials involving thousands of patients, compared the effects of the injectable medications with older methods.
Scientists emphasize that individuals who lose weight through dieting usually have a slower weight regain—around 0.1 kg a month—once they finish.
Understanding the Rapid Rebound
Nutrition scientists suggest the mechanism of the jabs is key to understanding the amplified regain.
The injections mimic a body's own chemical called GLP-1, which moderates hunger.
"Artificially providing the hormone concentrations far above than normal may cause the system to produce less of its endogenous hormone, and could lessen responsiveness to its effects," said Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this GLP-1 'fix' results in hunger is unsuppressed, making excessive eating far more likely."
A Lifelong Disease?
The NHS advise the jabs for people with weight-linked health risks, alongside recommended lifestyle changes.
A number of clinicians argue that, given the high risk of relapse, the treatment should be considered ongoing.
This view is supported by drug manufacturers, who state that the results "emphasize the persistent nature of obesity," akin to managing conditions like high blood pressure.
User Experiences
Users who have come off the medication explain a sudden return of cravings.
"It felt as if a switch activating and you become starving," recalled a patient.
This challenge is compounded if users have not established lasting dietary or behavioural changes during therapy.
Widespread Adoption
Survey data indicate that a significant number of people in the UK have used weight-loss jabs in the past year, with demand continuing to grow.
- Adoption is greater among women compared to men.
- The middle-aged demographic shows the greatest level of interest.
- Many access the drugs through private prescriptions rather than the NHS.
In conclusion, experts caution that while these medications are potent tools for weight loss, they are not a magic fix and lasting health benefits hinges on combined lifestyle changes.
